WEKO3
アイテム
{"_buckets": {"deposit": "23c04940-08af-425c-985b-19ee9473853c"}, "_deposit": {"created_by": 1, "id": "85108", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "85108"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00085108", "sets": ["1"]}, "author_link": ["1026125", "1026119", "1026108", "1026114", "1026111", "1026128", "1026112", "1026116", "1026124", "1026126", "1026120", "1026123", "1026109", "1026121", "1026110", "1026127", "1026122", "1026113", "1026115", "1026118", "1026117"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageStart": "67", "bibliographicVolumeNumber": "14", "bibliographic_titles": [{"bibliographic_title": "Pharmaceutics"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objectives: Early diagnosis of pancreatic cancer using current imaging modalities remains challenging. We have developed a new approach to identify the tumor lesions ≥ 3 mm in the pancreas by positron emission tomography (PET) with intraperitoneally administered 64Cu-labeled new anti-epidermal growth factor receptor (EGFR) antibody (encoded as NCAB001), called 64Cu-NCAB001 ipPET. Generally, in clinical research, radiometal-antibody complex must be prepared immediately before use at imaging site. To make 64Cu-NCAB001 ipPET become available to daily clinical practices sustainably, the NCAB001-chelator conjugate and 64Cu-NCAB001 must be characterized and stabilized. Methods: NCAB001 was manufactured under cGMP conditions. The conjugation of NCAB001 with bifunctional chelator (p-SCN-Bn-PCTA) was conducted, and the antibody-chelator conjugate (PCTA-NCAB001) was characterized by LC/MS and ELISA. Thereafter, to manufacture 64Cu-NCAB001 effectively, we developed a new formulation to stabilize the PCTA-NCAB001 and 64Cu-NCAB001. Results. An average of three PCTA chelators were conjugated per molecule of NCAB001. The relative binding potency of PCTA-NCAB001 was comparable to cetuximab. The formulation consisting of acetate buffer, glycine, and polysorbate-80 stabilized the PCTA-NCAB001 for a year-long storage. Additionally, this formulation enabled the stabilization of 64Cu-NCAB001 for up to 24 h after radiolabeling with sufficient radioactivity concentration for clinical use. Conclusion: These results may accelerate the future use of 64Cu-NCAB001 ipPET in the clinical settings for the early diagnosis and treatment of pancreatic cancer.", "subitem_description_type": "Abstract"}]}, "item_8_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "MDPI"}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3390/pharmaceutics14010067", "subitem_relation_type_select": "DOI"}}]}, "item_8_relation_17": {"attribute_name": "関連サイト", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.mdpi.com/1999-4923/14/1/67", "subitem_relation_type_select": "URI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1999-4923", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Hiroki, Matsumoto"}], "nameIdentifiers": [{"nameIdentifier": "1026108", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Chika, Igarashi"}], "nameIdentifiers": [{"nameIdentifier": "1026109", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tomoko, Tachibana"}], "nameIdentifiers": [{"nameIdentifier": "1026110", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukiko, Hihara"}], "nameIdentifiers": [{"nameIdentifier": "1026111", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Atsuo, Waki"}], "nameIdentifiers": [{"nameIdentifier": "1026112", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong"}], "nameIdentifiers": [{"nameIdentifier": "1026113", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sei, Yoshida"}], "nameIdentifiers": [{"nameIdentifier": "1026114", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kenichiro, Naito"}], "nameIdentifiers": [{"nameIdentifier": "1026115", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hiroaki, Kurihara"}], "nameIdentifiers": [{"nameIdentifier": "1026116", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Makoto, Ueno"}], "nameIdentifiers": [{"nameIdentifier": "1026117", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kimiteru, Ito"}], "nameIdentifiers": [{"nameIdentifier": "1026118", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tatsuya, Higashi"}], "nameIdentifiers": [{"nameIdentifier": "1026119", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yukie, Yoshii"}], "nameIdentifiers": [{"nameIdentifier": "1026120", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hiroki, Matsumoto", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026121", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Chika, Igarashi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026122", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tomoko, Tachibana", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026123", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukiko, Hihara", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026124", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Atsuo, Waki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026125", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026126", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tatsuya, Higashi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026127", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yukie, Yoshii", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026128", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Characterization and stabilization of a new 64Cu-labeled anti-EGFR antibody NCAB001 for the early detection of pancreatic cancer with positron emission tomography", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Characterization and stabilization of a new 64Cu-labeled anti-EGFR antibody NCAB001 for the early detection of pancreatic cancer with positron emission tomography"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/85108", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-12-28"}, "publish_date": "2021-12-28", "publish_status": "0", "recid": "85108", "relation": {}, "relation_version_is_last": true, "title": ["Characterization and stabilization of a new 64Cu-labeled anti-EGFR antibody NCAB001 for the early detection of pancreatic cancer with positron emission tomography"], "weko_shared_id": -1}
Characterization and stabilization of a new 64Cu-labeled anti-EGFR antibody NCAB001 for the early detection of pancreatic cancer with positron emission tomography
https://repo.qst.go.jp/records/85108
https://repo.qst.go.jp/records/851080bf0683f-4a5b-4886-bc6a-838f4d4f2118
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-12-28 | |||||
タイトル | ||||||
タイトル | Characterization and stabilization of a new 64Cu-labeled anti-EGFR antibody NCAB001 for the early detection of pancreatic cancer with positron emission tomography | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Hiroki, Matsumoto
× Hiroki, Matsumoto× Chika, Igarashi× Tomoko, Tachibana× Fukiko, Hihara× Atsuo, Waki× Zhang, Ming-Rong× Sei, Yoshida× Kenichiro, Naito× Hiroaki, Kurihara× Makoto, Ueno× Kimiteru, Ito× Tatsuya, Higashi× Yukie, Yoshii× Hiroki, Matsumoto× Chika, Igarashi× Tomoko, Tachibana× Fukiko, Hihara× Atsuo, Waki× Zhang, Ming-Rong× Tatsuya, Higashi× Yukie, Yoshii |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objectives: Early diagnosis of pancreatic cancer using current imaging modalities remains challenging. We have developed a new approach to identify the tumor lesions ≥ 3 mm in the pancreas by positron emission tomography (PET) with intraperitoneally administered 64Cu-labeled new anti-epidermal growth factor receptor (EGFR) antibody (encoded as NCAB001), called 64Cu-NCAB001 ipPET. Generally, in clinical research, radiometal-antibody complex must be prepared immediately before use at imaging site. To make 64Cu-NCAB001 ipPET become available to daily clinical practices sustainably, the NCAB001-chelator conjugate and 64Cu-NCAB001 must be characterized and stabilized. Methods: NCAB001 was manufactured under cGMP conditions. The conjugation of NCAB001 with bifunctional chelator (p-SCN-Bn-PCTA) was conducted, and the antibody-chelator conjugate (PCTA-NCAB001) was characterized by LC/MS and ELISA. Thereafter, to manufacture 64Cu-NCAB001 effectively, we developed a new formulation to stabilize the PCTA-NCAB001 and 64Cu-NCAB001. Results. An average of three PCTA chelators were conjugated per molecule of NCAB001. The relative binding potency of PCTA-NCAB001 was comparable to cetuximab. The formulation consisting of acetate buffer, glycine, and polysorbate-80 stabilized the PCTA-NCAB001 for a year-long storage. Additionally, this formulation enabled the stabilization of 64Cu-NCAB001 for up to 24 h after radiolabeling with sufficient radioactivity concentration for clinical use. Conclusion: These results may accelerate the future use of 64Cu-NCAB001 ipPET in the clinical settings for the early diagnosis and treatment of pancreatic cancer. | |||||
書誌情報 |
Pharmaceutics 巻 14, 号 1, p. 67, 発行日 2022-01 |
|||||
出版者 | ||||||
出版者 | MDPI | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1999-4923 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.3390/pharmaceutics14010067 | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.mdpi.com/1999-4923/14/1/67 |